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second patient were within the same 
subgroup, but similarity in nucleotide 
sequences was only 82.5%. This result 
suggests that this patient was infected 
with 2 different virus strains of HRV-A 
and a strain of HRV-C.
Comparison of the HRV-A strains 
with  the  HRV-C  strain  showed  that 
they belonged to different subgroups 
and had low similarity for nucleotide 
sequences. The second patient had 3 
distinct  rhinovirus  infections  over  3 
months, and each was associated with 
illness requiring hospitalization. Both 
patients had underlying diseases, reac-
tive airway diseases, and repeated epi-
sodes of RTI that may have rendered 
them vulnerable to reinfection, com-
promising their immune responses.
Complete  coding  sequences  of 
HRV-A and HRV-C have been deter-
mined (4,7). However, little is known 
about their involvement in the patho-
genesis  of  recurrent  wheezing  in 
young  children. According  to  recent 
reports, HRV-C has been detected in 
hospitalized children with lower RTI 
in the People’s Republic of China (5). 
Possible association of novel infection 
with HRV and exacerbation of asthma 
in children has also been reported (6). 
We  report  HRV-A  and  HRV-C  co-
infections  in  conjunction  with  other 
respiratory viruses, such as RSV, as a 
potential cause of recurrent wheezing 
in infants with acute lower RTIs. Co-
infections  with  HRV-A  and  HRV-C 
may contribute to increased virulence 
and subsequent pathogenesis of other 
respiratory viruses. Additional studies 
will be required to further explore the 
clinical role of novel HRVs.
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Extensively  
Drug-Resistant  
Acinetobacter  
baumannii 
To  the  Editor:  In  the  1990s, 
patients  infected  with  vancomycin-
resistant  Enterococcus  faecium  were 
successfully treated with new antimi-
crobial drugs. However, it is unlikely 
that new antimicrobial drugs will be 
available  in  the  near  future  to  treat 
patients  infected  with  gram-negative 
pathogens  such  as  Acinetobacter 
baumannii (1). No new antimicrobial 
drugs active against this organism are 
currently in clinical trials (www.clini-
caltrials.gov). We report a patient in-
fected with A. baumannii that lacked 
susceptibility  to  all  commercially 
available antimicrobial drugs.
The patient, a 55-year-old woman, 
had a prolonged stay in an intensive 
care  unit  at  the  University  of  Pitts-
burgh  Medical  Center  (Pittsburgh, 
PA, USA) after undergoing lung trans-
plantation. In the tenth postoperative 
week,  ventilator-associated  pneumo-
nia developed, which was caused by 
A. baumanni that lacked susceptibil-
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ity  to  all  antimicrobial  drugs  tested 
except  colistin  (MIC  0.5  µg/mL). 
Therapy with colistin and tigecycline 
was begun. Colistin was administered 
intravenously  and  by  inhalation. Al-
though the pneumonia showed radio-
graphic response to the antimicrobial 
drug therapy, A. baumannii continued 
to be isolated from respiratory secre-
tions on numerous occasions. Despite 
another course of therapy with colistin 
and  cefepime,  the  patient  never  re-
covered from respiratory failure. She 
eventually  died  of  sepsis  caused  by 
vancomycin-resistant E. faecium. An 
A. baumannii isolate obtained just be-
fore she died lacked susceptibility to 
all commercially available antimicro-
bial drugs (Table).
Multidrug-resistant  A.  bauman-
nii has emerged as a substantial prob-
lem  worldwide  (2).  Such  strains  are 
typically  resistant  to  all  β-lactams 
and fluoroquinolones and require sal-
vage therapy with colistin, amikacin, 
or tigecycline. Unfortunately, notably 
high-level  resistance  to  colistin  and 
amikacin was found in the isolate we 
have  described  (Table).  Tigecycline, 
a newly available glycylcycline anti-
microbial drug, showed intermediate 
susceptibility.  No  randomized  trials 
have  been  performed  to  specifically 
evaluate  combination  antimicrobial 
drug therapy for treatment of infection 
with A. baumannii.
Considerable media attention has 
been paid to extensively drug-resistant 
(XDR) strains of Mycobacterium tu-
berculosis ( 3).  Infections  with  XDR 
strains are extremely difficult to treat 
and pose considerable infection con-
trol issues. We recently proposed that 
gram-negative bacilli lacking suscep-
tibility to all commercially available 
antimicrobial  drugs  also  be  referred 
to as XDR because no therapeutic op-
tions are available (4).
Numerous outbreaks of A. bau-
mannii infection have been reported 
worldwide  (5).  Unfortunately,  mul-
tidrug-resistant A. baumannii strains 
have  become  endemic  in  some  in-
stitutions.  Experimental  and  clini-
cal isolates lacking susceptibility to 
colistin,  often  considered  the  drug 
of last resort, are increasingly being 
reported  (6–8).  Therefore,  we  alert 
healthcare  workers  to  the  need  for 
stringent  care  in  adhering  to  infec-
tion control precautions when caring 
for  patients  infected  with  XDR  A. 
baumannii. Use of contact isolation 
precautions,  enhanced  environmen-
tal  cleaning,  removal  of  sources  of 
infection from the hospital environ-
ment, and prudent use of antimicro-
bial drugs can contribute to control 
of  such  outbreaks  (5).  Fortunately, 
no spread of the XDR strain affect-
ing this patient occurred. A crisis is 
looming  should  XDR  A.  bauman-
nii become established pathogens in 
hospitals.
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Table. MICs and antimicrobial drug susceptibility for an extensively drug-resistant strain 
of Acinetobacter baumannii*
Drugs MIC, ȝg/mL Interpretation 
Carbapanems 
  Imipenem  >32 Resistant
  Meropenem  >32 Resistant
Penicillins 
  Ampicillin/sulbactam  32 Resistant
  Piperacillin/tazobactam  >256 Resistant
Cephalosporins
  Ceftazidime  48 Resistant
  Cefepime  16 Intermediate
Aminoglycosides 
  Gentamicin  >256 Resistant
  Tobramycin  >256 Resistant
  Amikacin  >256 Resistant
Others
  Ciprofloxacin  >32 Resistant
  Tigecycline  2 Intermediate
  Colistin  >1,024 Resistant
*Susceptibility testing was performed by using the Etest (AB Biodisk, Solna, Sweden), except for 
colistin, for which the standard agar dilution method was used. Interpretation was according to 
breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA). 
No tigecycline breakpoints for Acinetobacter spp. are provided by the CLSI, the European 
Committee on Antimicrobial Susceptibility Testing (Basel, Switzerland), or the US Food and Drug 
Administration (Silver Spring, MD, USA). Breakpoints of the British Society for Antimicrobial 
Chemotherapy (Birmingham, UK) are indicated for tigecycline. 
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Cryptosporidium 
Pig Genotype II in 
Immunocompetent 
Man
To  the  Editor:  Protozoan  para-
sites from the genus Cryptosporidium 
have been described as a cause of diar-
rheal disease in immunodeficient and 
immunocompetent  humans  world-
wide.  Although  C.  hominis  and  C. 
parvum (cattle genotype) cause most 
infections, humans can be infected by 
several  other  Cryptosporidium  spe-
cies or genotypes: C. meleagridis; C. 
felis; C. canis; C. suis; C. muris; C. 
andersoni; C. hominis monkey geno-
type;  C.  parvum  (mouse  genotype); 
and Cryptosporidium rabbit genotype, 
deer genotype, skunk genotype, horse 
genotype,  and  chipmunk  genotype 
I  (1–4).  Wild  and  domestic  animals 
are  sources  of  infection  for  humans 
(and  other  animals)  and  important 
contributors to contamination of food 
and drinking water; many nonhuman 
Cryptosporidium species or genotypes 
are detected in untreated water (5). We 
examined the diversity of Cryptospo-
ridium spp. in immunocompetent per-
sons in South Bohemia in the Czech 
Republic.
Diarrheal fecal samples (n = 457) 
from  203  anonymous  immunocom-
petent patients <69 years of age with 
suspected  cryptosporidiosis  (at  least 
2 samples/patient/3-day period) were 
obtained  from  local  health  depart-
ments  and  public  hospitals  in  South 
Bohemia during 2005–2007. Samples 
were  examined  for  Cryptosporidium 
oocysts by using aniline-carbol-meth-
yl violet staining and light microscopy 
at × 1,000 magnification (6). The mi-
croscopically  positive  samples  were 
confirmed by DNA sequencing of the 
small subunit (SSU) rRNA gene. Total 
DNA was extracted from 200–300 mg 
stool by using the QIAamp DNA Stool 
Mini Kit (QIAGEN, Hilden, Germa-
ny), following the manufacturer’s in-
structions, after previous homogeniza-
tion and disruption of oocysts with the 
Mini-BeadBeater  (Biospec  Products, 
Bartlesville, OK, USA). An ≈830-bp 
fragment of the SSU rRNA gene was 
amplified by nested PCR according to 
Jiang et al. (7). Purified PCR products 
were sequenced in both directions on an 
ABI3130 sequencer analyzer (Applied 
Biosystems, Foster City, CA, USA) by 
using the secondary PCR primers and 
the BigDye Terminator v3.1 Cycle Se-
quencing  Kit  (Applied  Biosystems). 
Sequences were assembled by using 
Chromas  Pro  (www.technelysium.
com.au/chromas.html)  and  aligned 
with reference sequences using Clust-
alX  (ftp://ftp-igbmc.u-strasbg.fr/pub/
ClustalX). The BLAST server (www.
ncbi.nlm.nih.gov/BLAST)  was  used 
for DNA database searches. The SSU 
rRNA gene partial sequences of the 7 
patient isolates have been submitted to 
GenBank (Table).
Of the 203 patients, 7 (3.4%) (6 
children and 1 adult) had positive re-
sults for Cryptosporidium spp. More-
over, all samples obtained from these 
persons during the 3-day period were 
Cryptosporidium  spp.  positive;  par-
tial sequences of the Cryptosporidium 
SSU rRNA gene were obtained from 
all positive samples identifying 3 dif-
ferent species or genotypes of Cryp-
tosporidium.  Five  were  C.  parvum 
(bovine genotype), 1 was C. hominis, 
and 1 contained the Cryptosporidium 
pig  genotype  II  (Table).  Cryptospo-
ridium pig genotype II was found in 
stool samples from a 29-year-old man 
who  also  was  infected  with  Giardia 
intestinalis (assemblage A) (data not 
shown).
Only  C.  parvum  (bovine  geno-
type),  C.  hominis,  and  Cryptospo-
ridium  rabbit  genotype  have  been 
implicated  in  waterborne  outbreaks 
of cryptosporidiosis in humans. Fur-
ther studies are needed to determine 
the  potential  of  other  cryptosporidia 
of animal origin. Recent genetic and 
biologic characterization studies have 
identified  2  distinct  host-adapted 
cryptosporidia  in  pigs,  C.  suis  and 
Cryptosporidium  pig  genotype  II. 
Furthermore,  both  above-mentioned 
cryptosporidia  have  been  identified 
in untreated water (8). Pigs could be 
sources of Cryptosporidium water and 
food pollution and a consequent risk 
to public health.
Although  human  infection  with 
C. suis has been previously described 
(9), human infection with Cryptospo-
ridium pig genotype II has been never 
reported.  This  genotype  was  found 
in  diarrheal  stool  of  1  adult  patient 
in  this  study.  However,  onset  of  di-
arrhea  could  have  been  caused  by 
co-infection  with  G.  intestinalis  (as-
semblage A), which recently also has 
been described in pigs (10). Contact 
with infected animals and ingestion of 
contaminated food or water could be 
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